New Horizons in Treating Obstructive Hypertrophic Cardiomyopathy (oHCM)
For years, the medical approach to obstructive hypertrophic cardiomyopathy (oHCM) has been focused on a singular goal: symptom management. Because there is no cure for the condition, physicians relied on medications and procedures to prevent complications and improve quality of life. However, the therapeutic landscape is shifting. We are moving away from simply masking symptoms and toward treatments that target the underlying biological causes of the disease.
The arrival of targeted therapies marks a turning point for patients. With new approvals and a pipeline of emerging treatments, those living with limiting symptoms now have more options than ever before.
Understanding Obstructive Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy occurs when the heart muscle becomes abnormally thick (hypertrophied). In the obstructive form (oHCM), this thickening occurs in a way that blocks blood flow from the left ventricle to the aorta, the body’s main artery. This obstruction forces the heart to work harder to pump blood, leading to symptoms such as shortness of breath, chest pain, and fainting.
Traditionally, treatment focused on reducing the heart’s contractility and slowing the heart rate to allow more time for the ventricle to fill. This was typically achieved using beta-blockers or calcium channel blockers. While effective for some, these treatments do not address the molecular mechanism driving the obstruction.
The Breakthrough: Cardiac Myosin Inhibitors
The most significant advancement in recent years is the introduction of Mavacamten (brand name Camzyos). Approved by the FDA in 2022, Mavacamten is the first medication specifically designed to target the underlying cause of oHCM.
Mavacamten belongs to a class of drugs called cardiac myosin inhibitors. To understand how it works, it helps to view the heart as a mechanical pump. In oHCM, the “cross-bridges” between myosin and actin—the proteins that allow heart muscles to contract—are too numerous or too active. This creates excessive contraction and contributes to the obstruction. Mavacamten reduces the number of these active cross-bridges, easing the obstruction and improving the flow of blood out of the heart.
The Future of oHCM Therapy
The approval of Mavacamten is only the beginning. The medical community is now on the cusp of expanding the oHCM arsenal with additional therapies. According to Sara Saberi, MD, an assistant professor in the division of cardiovascular medicine at the University of Michigan in Ann Arbor, this is a hopeful era for patients. Dr. Saberi notes that people with limiting symptoms have significantly more options currently available and more “coming down the pike that are really worthwhile.”
Over the next five to ten years, patients can expect a more personalized approach to treatment. This may include more refined pharmacological options and potentially genetic interventions that address the mutations causing the heart muscle to thicken in the first place.
How to Access Cutting-Edge Treatments
If you or a loved one is living with oHCM, accessing the latest therapies requires a proactive approach. Because these medications are specialized and require careful monitoring, the following steps are recommended:
- Consult a Specialist: Seek a cardiologist who specializes in hypertrophic cardiomyopathy. General cardiologists may not always be current on the latest myosin inhibitors or clinical trial data.
- Request a Comprehensive Evaluation: Ensure you have a current echocardiogram or cardiac MRI to determine if your condition is obstructive, as targeted therapies like Mavacamten are specifically for the obstructive form.
- Inquire About Clinical Trials: For those who do not respond to current medications, clinical trials offer a pathway to access next-generation therapies before they are widely available.
- Shift in Care: Treatment is moving from general symptom management to disease-modifying therapies.
- Targeted Medication: Mavacamten (Camzyos) targets the underlying cause of obstruction by inhibiting cardiac myosin.
- Positive Outlook: New therapies are currently in development, providing more hope for those with severe symptoms.
- Specialized Care: Accessing new treatments often requires a referral to a cardiomyopathy specialist.
Frequently Asked Questions
Is Mavacamten a cure for oHCM?
No. While Mavacamten targets the underlying mechanism of the obstruction to improve symptoms and function, it is not a cure. It is a treatment used to manage the disease more effectively.
Who is eligible for cardiac myosin inhibitors?
These medications are specifically for patients with the obstructive form of hypertrophic cardiomyopathy. Patients without obstruction may require different management strategies.
What should I ask my doctor about oHCM?
Ask: “Am I a candidate for cardiac myosin inhibitors?” and “Are there any ongoing clinical trials for oHCM that would be appropriate for my specific genetic profile or symptom level?”